Effect of adding umbilical cord blood derived stem cells to haploidentical stem cell transplant (haplo-cord) on post-transplant survival and graft-versus-host disease in patients with hematological malignancies: A systematic review and meta-analysis.

Transpl ImmunolAug 26, 2026 (epub)
Clinical ResearchHematologyOncology (Medical)

Muhammad Zain Raza, Anas Babar, Hafiz Muhammad Ehsan Arshad et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the impact of adding umbilical cord blood-derived stem cells to haploidentical stem cell transplantation (haplo-cord) in patients with hematological malignancies. The analysis of 12 studies revealed that haplo-cord significantly reduced chronic graft-versus-host disease (GvHD) (OR=0.62) and improved overall survival (HR=0.68) compared to haplo-SCT alone.

Key findings

  • Haplo-cord transplantation reduced chronic GvHD with an odds ratio of 0.62.
  • Overall survival was significantly better with haplo-cord (HR=0.68).
  • Event-free survival also favored haplo-cord (HR=0.61).
  • Relapse at 3 years was significantly lower with haplo-cord (OR=0.54).

Why it matters

The findings suggest that haplo-cord transplantation may enhance patient outcomes by reducing the risk of chronic GvHD and improving survival rates, which is critical for managing hematological malignancies.

Source

PubMed · PMID 42637104

Published in Transpl Immunol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Hematology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.